Key facts
- It has raised $10.0M; the latest was Early Stage VC ($10.0M) in Jun 2025.
- Notable investors include JNP Global.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Palladium Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Palladium Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Palladium Biotech
Developer of antimicrobial and anticancer treatment agents designed to address super bacteria and improve cancer treatment precision. The company offers development of MoSTT-CelSuR technology, an anticancer drug discovery method that addresses false positives in existing methods, providing biopharmaceutical companies with the development of ultra-precision anticancer drugs.
- Sector
- Healthcare
- HQ
- Daejeon, South Korea
- Founded
- 2021
- Ownership
- Privately Held (backing)
Palladium Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Palladium Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Palladium Biotech in its N-PORT filings yet. We sweep new filings monthly.